<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BEAEC84-D2AD-4AB4-8B78-C3D847CAE340"><gtr:id>7BEAEC84-D2AD-4AB4-8B78-C3D847CAE340</gtr:id><gtr:name>Calixar</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BEAEC84-D2AD-4AB4-8B78-C3D847CAE340"><gtr:id>7BEAEC84-D2AD-4AB4-8B78-C3D847CAE340</gtr:id><gtr:name>Calixar</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0EE2CE59-D7FC-4EDE-81EF-03B5D9BD5F25"><gtr:id>0EE2CE59-D7FC-4EDE-81EF-03B5D9BD5F25</gtr:id><gtr:firstName>Jason</gtr:firstName><gtr:otherNames>Ronald</gtr:otherNames><gtr:surname>Schnell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901012"><gtr:id>7F069E3E-FBE2-477E-80E3-BE171E31003C</gtr:id><gtr:title>Mechanism of Inhibition of Viral and Neuronal Pore Loop Ion Channels by the Adamantanes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901012</gtr:grantReference><gtr:abstractText>Essentially all living cells have channel-like proteins embedded in their cell walls. The presence of these channels selectively allow certain classes of charged molecules, or ions, to pass into or out of the cellular interiors, as cell walls by themselves are normally impermeable to such molecules. Channels are often critical components of cells, and opening and closing ion channels is at the centre of many normal cellular processes such as cell fate decisions or intercellular communication. Ion channels are also at the root of some abnormal processes that arise from genetic mutations such as multiple sclerosis, or have functions that are essential for pathogen viability such as in the influenza virus. For this reason, many useful drugs act by forcing ion channels to open or close. One family of drugs that function in this way are the adamantanes. They bind to, and close, a surprisingly wide variety of ion channels, including a proton channel in the flu virus called M2, and calcium channels that are found in humans at neuronal synapses called NMDA receptors, which are involved in memory and learning. For these reasons, adamantanes are prescribed both for the treatment of flu infections, and to alleviate the symptoms of neurodegeneration associated with diseases such as Parkinsons and Alzheimers. Drugs typically interact specifically with proteins such as ion channels at one particular site, and knowing the precise physical properties of those interactions can facilitate design of more specific, and therefore more effective or less toxic drugs. In previous work, we elucidated the physical location at which the adamantanes bind to the flu virus ion channel. Unfortunately, little is known about the same process in the NMDA receptor. We now hope to use what we learned in the M2 case, to understand what physical interactions are needed for binding to the NMDA receptors. In addition, adamantanes such as amantadine and memantine are part of a larger class of potentially therapeutic compounds that bind to the NMDA receptor. Thus, understanding the behaviour of the adamantanes may be broadly applicable for guiding development of more effective drug treatments for neurodegenerative diseases.</gtr:abstractText><gtr:technicalSummary>Adamantane-based drugs inhibit a wide range of ion channels with different structures and ion selectivities. Historically, they have been used to treat influenza infections because they inhibit the virus M2 proton channel. The spread of resistant virus has, however, rendered the adamantanes essentially useless. Recent experiments in this lab have suggested that the M2 adamantane binding site is composed of functionally important, and therefore highly conserved, residues; there is therefore the possibility that alternative antiviral drugs could be found by targeting this conserved pocket. Thus, Part A of this proposal is aimed at determining the components of M2 that are critical for drug binding, with the ultimate goal of informing the design of next generation antivirals. Adamantanes are also used for the treatment of dementia associated with Alzheimers and Parkinsons diseases. The therapeutic target for this indication is the ion channel domain of the ionotropic NMDA receptor. Although, high-resolution structures of the intact ionotropic NMDA receptor have not been determined due to its size and complexity, the viral ion channel Kcv is a structurally homologous pore-loop ion channel that is also inhibited by the adamantane amantadine. Thus, Kcv is a useful surrogate for studies that focus on adamantane binding and inhibition of this class of ion channels. In Part B and C of the proposal, we will use techniques developed for the investigation of adamantane binding to M2 to establish and exploit an experimental system for the study of adamantane binding to Kcv at the atomic level, and by extension, to the NMDA receptor ion channel. Functional studies using liposomal ion fluxes will validate and extend the structural work. It is anticipated that a detailed characterization of the position and structural and dynamic effects of drug binding within the context of these disparate ion channel structures will provide information for new approaches to drug design for this class of valuable ion channel inhibitors.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-19</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-20</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>499308</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>CALIXAR</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Use of novel detergents for membrane protein structure and ligand binding.</gtr:description><gtr:id>A7A66302-CA09-41EB-853B-3606E665A8FF</gtr:id><gtr:impact>Established conditions for reconstitution of M2 and other membrane proteins into the detergents.</gtr:impact><gtr:outcomeId>AMFNz9ZbPHX-1</gtr:outcomeId><gtr:partnerContribution>Contributed the detergent compounds free of charge.</gtr:partnerContribution><gtr:piContribution>Tested a range of novel detergent-like compounds for their utility in solution NMR studies of the M2 ion channel, as well as other membrane proteins.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Glycobiology Institute</gtr:department><gtr:description>p7 iminosugar interactions</gtr:description><gtr:id>2C305526-39BB-4D15-93B0-AC01CF730ED9</gtr:id><gtr:impact>Manuscript describing the results is being planned. The project is multidisciplinary: NMR, ion channel conductance assays, characterisation of iminosugar efficacy.</gtr:impact><gtr:outcomeId>SzMdx3rRrKu-1</gtr:outcomeId><gtr:partnerContribution>Production of p7 protein.</gtr:partnerContribution><gtr:piContribution>Design, execution and analysis of NMR studies for the structural characterisation of the p7 ion channel from hepatitis C, and the interactions of p7 with iminosugars, which are promising drug candidates.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Virus Art Exhibition</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1F9EBBC1-916C-44C6-891C-E654777116CB</gtr:id><gtr:impact>I consulted on an art exhibit curated by Dr. Shirley Wheeler (University of Sunderland) and hosted at St. John's College in Oxford. The exhibit was widely advertised and open to the public for four weeks. The title of the exhibit was &amp;quot;Virus: Bad News Wrapped in Protein&amp;quot;. It involved several artists with whom I discussed my work, and I was present at the opening.

The event was successful, and collaborations on future exhibits with Dr. Shirley Wheeler are anticipated.</gtr:impact><gtr:outcomeId>L6kJFKE8ZEG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Oxford High)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5844702B-082D-459D-BFE8-2D11D1294189</gtr:id><gtr:impact>~20 students and 3 teachers attended. Very good discussion afterwards.

Several others from the department have been invited to speak.</gtr:impact><gtr:outcomeId>qKzaiqesfVR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Describes a system for studying interactions of small molecules with the influenza M2 protein.</gtr:description><gtr:grantRef>G0901012</gtr:grantRef><gtr:id>643A9CF9-E902-4D8E-BF71-C4A59FE45C5F</gtr:id><gtr:impact>Used to further characterise drug interactions with the influenza M2 protein.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>RFdJeM59bWu</gtr:outcomeId><gtr:patentId>WO2009055010</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Systems and Methods for Studying Influenza</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An experimental system was developed that enables high resolution observation of interactions of an influenza M2 protein that is associated with pandemic flu.</gtr:description><gtr:id>1EE73FC4-BBF6-4FDF-A339-4199DD4E5C6E</gtr:id><gtr:impact>Has enabled a better understanding of previously reported data on M2.</gtr:impact><gtr:outcomeId>dBzCFMAcQPH</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Swine M2/lipid interactions.</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>63891E9A-77D9-4B6D-8F9C-FAB45D9BFCC3</gtr:id><gtr:title>Mechanism of drug inhibition and drug resistance of influenza A M2 channel.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a47a25819ffe1ed24ba56fe970531e5"><gtr:id>9a47a25819ffe1ed24ba56fe970531e5</gtr:id><gtr:otherNames>Pielak RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_15213_13_19383794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>000E3795-867B-485A-86FF-EA4314E64206</gtr:id><gtr:title>Isotropic bicelles stabilize the juxtamembrane region of the influenza M2 protein for solution NMR studies.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a25dfa8fb1b7d846d3d4bad9d3f5f66"><gtr:id>7a25dfa8fb1b7d846d3d4bad9d3f5f66</gtr:id><gtr:otherNames>Claridge JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>pm_15213_23_24168642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9A3CFEB-1E74-402C-AE31-5340CB391E01</gtr:id><gtr:title>Position and orientational preferences of drug-like compounds in lipid membranes: a computational and NMR approach.</gtr:title><gtr:parentPublicationTitle>Physical chemistry chemical physics : PCCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34289d1f3f86c00e4e17601fafeefa31"><gtr:id>34289d1f3f86c00e4e17601fafeefa31</gtr:id><gtr:otherNames>Ma J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1463-9076</gtr:issn><gtr:outcomeId>56b0bbee181c19.29753217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92CB134B-B6B0-4B74-9F89-BAF0A8BA9E68</gtr:id><gtr:title>Bacterial production and solution NMR studies of a viral membrane ion channel.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a25dfa8fb1b7d846d3d4bad9d3f5f66"><gtr:id>7a25dfa8fb1b7d846d3d4bad9d3f5f66</gtr:id><gtr:otherNames>Claridge JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_15213_23_22167674</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901012</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>